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ABSTRACT
Disseminated intravascular coagulation (DIC) is an acquired syndrome characterized by the widespread activation of coagulation. It can 
present as an acute life-threatening emergency or as a chronic process. Mortality is highly dependent on the reversibility of the aetiology 
and degree of coagulation impairment, so treatment of the underlying cause is vital. The authors present the case of a 57-year-old man 
whose inaugural presentation of lung cancer was chronic DIC, characterized by three thrombotic events, followed by acute DIC, culminating 
in death. Metastatic lung cancer was diagnosed only after death.
LEARNING POINTS
• Disseminated intravascular coagulation (DIC) is an acquired syndrome characterized by systemic intravascular activation of coagulation, 
originating from and causing damage to the microvasculature, which can present as an acute or chronic condition, manifested by bleeding 
or thrombotic events.
• Unexplained thrombotic events should raise suspicion of chronic DIC.
•	 Treatment	will	fail,	despite	supportive	measures,	if	the	cause	of	the	DIC	is	not	identified.
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CASE DESCRIPTION
A 57-year-old man with a previous history of arterial hypertension, previous smoking (40 pack-years), deep vein thrombosis (DVT) on 
rivaroxaban and recent hospitalization for Takotsubo cardiomyopathy, was admitted into the emergency department with acute dyspnoea, 
haemoptysis and syncope. On admission, he was polypnoeic, hypoxaemic and hypotensive. Arterial blood gas showed type 1 respiratory 
failure (pO
2
 54 mmHg) and hypocapnia (pCO
2
 30 mmHg). Blood work revealed increased D-dimers (25.54 mg/l, normal <0.50) and EKG 
had	an	S1Q3T3	pattern.	Thoracic	CT	angiography	confirmed	a	pulmonary	embolism,	 revealing	a	peripheral	pulmonary	embolism	of	 the	
lower left lobe, bilateral pleural effusion and bilateral lower lobe consolidation. During hospitalization, the patient initially experienced 
easy fatigability, dyspnoea and hypoxaemia requiring a high fraction of inspired oxygen. Given the recurrent venous thrombosis while 
on anticoagulation, additional investigations were performed: thrombophilia testing showed mild positive lupus anticoagulant, negative 
anticardiolipin	and	anti-beta2-glycoprotein	antibodies,	and	negative	serologic	tests	for	human	immunodeficiency	virus,	hepatitis	B	and	C;	
abdominopelvic CT revealed mild to moderate pleural effusion, left lower lobe consolidation and bilateral augmented suprarenal glands. The 
patient	was	discharged	after	10	days	on	levofloxacin	and	referred	to	an	internal	medicine	appointment.	Despite	inconclusive	studies,	in	light	
of high suspicion of a paraneoplastic syndrome caused by an occult malignancy, we opted for anticoagulation with tinzaparin.
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A	month	later,	the	patient	was	readmitted	for	a	spontaneous	dorsal	haematoma.	Physical	examination	identified	decreased	breath	sounds	
on the left lower lung and a dorsal haematoma measuring 10×5 cm. Laboratory analysis showed thrombocytopenia (103,000/µl, normal 
150–400,000), a prolonged prothrombin time (PT) (18.7 sec, normal 10.6–13.5) and an increased international normalized ratio (INR) 
(1.59).	Hypoxemia	was	identified	(pO
2
	51	mmHg)	and	on	chest	radiography	there	was	evidence	of	right	pulmonary	hilar	infiltrate.	DIC	was	
considered and anticoagulation was stopped. There was clinical degradation with ecchymosis on venipuncture sites and haemoptysis, as 
well as worsening thrombocytopenia (93,000/µl), aggravated coagulation times (PT 26.0 sec, INR 2.23), immeasurable D-dimers (>32.50 
mg/l)	and	hypofibrogenemia	(162	mg/dl,	normal	180–350).	Thoracic	CT	excluded	new	pulmonary	embolisms	and	showed	lung	parenchyma	
alterations,	so	bronchofibroscopy	was	scheduled.
Given the unfavourable evolution, the patient was transferred to the intensive care unit. During the following hours, there was sudden 
loss of consciousness, preceded by nausea and vomiting, with altered consciousness (Glasgow coma score 7). Head CT showed a right 
frontal haematoma with rupture to the subarachnoid and subdural space, associated with cerebral compression with subfalcine and central 
herniation.	Mannitol,	fibrinogen,	 fresh	 frozen	plasma	and	a	platelet	pool	were	administered.	Neurosurgery	consultation	considered	the	
patient	unfit	for	surgical	intervention	due	to	his	multiple	comorbidities	and	previous	anticoagulation.	Despite	supportive	measures,	there	
was continuing intracranial bleeding (Fig. 1) and the patient ultimately evolved into brain death. Given the high suspicion of an occult 
malignancy,	he	was	considered	unfit	for	transplantation.	After	authorization,	an	autopsy	was	performed	which	identified	a	1.5	cm	left	lower	
lobe tumour with ipsilateral and contralateral nodal metastasis, as well as contralateral lung, suprarenal glands and splenic metastasis. There 
were also posterior heart wall ischaemic lesions, despite permeable coronary vessels, acute pancreatitis, haemorrhagic kidney lesions and 
haemorrhagic cystitis.
Figure 1. Axial section of head CT with extensive bilateral subarachnoid haemorrhage and 
ventricular flooding
DISCUSSION
Venous thromboembolism may be the inaugural presentation of neoplasia in an otherwise healthy person. Cancer patients have a four to 
seven times greater chance of developing thrombotic events, ranging from venous or arterial thrombosis to systemic syndromes, such as 
DIC. The main cancer-related risk factors are the primary tumour site, staging, therapy (mostly chemotherapy, hormonal and anti-angiogenic 
agents), utilization of erythropoiesis-stimulating agents, the presence of central venous catheters and blood transfusions[1]. 
As	proposed	by	the	Scientific	and	Standardization	Committee	(SSC)	of	the	International	Society	on	Thrombosis	and	Haemostasis	(ISTH),	DIC	
is an acquired syndrome characterized by the intravascular activation of coagulation with loss of localization, originating from and causing 
damage	to	the	microvasculature,	which	if	sufficiently	severe	can	cause	organ	dysfunction.	It	can	present	as	an	acute	condition	caused	by	
a decompensated haemostatic system, designated as overt, acute or decompensated DIC, or as a chronic subclinical process, caused by a 
compensated haemostatic system, called non-overt, chronic or compensated DIC. It can present with various clinical features, ranging from 
abnormal coagulation tests to catastrophic thrombotic and bleeding manifestations. It seems to be underdiagnosed with an incidence of 
10–15%, emphasizing the need for clinical awareness of this condition[2]. DIC is emerging as a paraneoplastic syndrome and, as we know, 
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trachea, bronchus and lung cancers were the sixth leading cause of death in 2016 according to World Health Organization statistics[3].
Regarding our clinical case, our main hypothesis had been a paraneoplastic syndrome linked to an occult neoplasia, given the recurrent 
thrombotic manifestations—the DVT, the myocardial infarction and the pulmonary embolism. When our patient presented with a 
spontaneous haematoma, generalized oozing from intravenous catheter sites and thrombocytopenia, our main hypothesis was acute DIC. 
All	 laboratory	markers	were	present:	 trend	reduction	 in	 thrombocytopenia,	prolongation	of	coagulation	times,	hypofibrinogenemia	and	
increased	D-dimer.	The	trend	reduction	reflected	worsening	DIC[2,4,5].	We	had	not	identified	an	obvious	underlying	condition,	so	we	could	
only	offer	supportive	measures.	There	was	not	sufficient	time	for	a	diagnosis	given	the	catastrophic	evolution.	Ultimately,	there	were	distinct	
signs of a worse outcome: central nervous system effects, worsening laboratory abnormalities and stage IV lung cancer.
Should we have suspected DIC all along? Could we have diagnosed cancer sooner? Would it have made a difference? We are aware of acute 
DIC with bleeding and thrombotic manifestations, but not of chronic DIC with laboratory-only alterations or localized thromboembolic 
events. Chronic DIC can progress to acute DIC when consumption of platelets and coagulation factors exceeds their production and the 
liver	can	no	longer	clear	the	fibrin	degradation	products[6]. In short, our clinical case can be interpreted as chronic DIC that culminated in 
acute DIC. 
Even if we had previously diagnosed cancer, solid tumours do not respond as well to standard treatment as other DIC causes, despite equal 
outcome[1, 4]. Regarding mortality, it appears to be higher among lung cancer patients, especially in early stage and advanced malignancies, as 
in the case presented[1,4,7]. Moreover, it remains unclear whether the coagulopathy in itself carries a worse outcome or if it rather represents 
an epiphenomenon of an underlying disease with a worse prognosis. Risk factors for death include increasing age, severity of organ 
dysfunction and haemostatic abnormalities, the last two presented by our patient[2,4,8].
This	case	is	an	example	of	a	catastrophic	paraneoplastic	syndrome	caused	by	lung	cancer	identified	only	after	death.	It	reinforces	the	strong	
relationship between unexplained venous thromboembolism and cancer, as well as the need for a higher degree of suspicion for DIC.
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